Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 1285-2 (MIR1285-2) is a short, non-coding RNA molecule approximately 22 nucleotides in length, involved in post-transcriptional regulation of gene expression by binding target mRNA and promoting its degradation or inhibiting its translation[3]. In humans, MIR1285-2 is encoded on chromosome 2p13.3. Its mature sequence is identical to that from MIR1285-1. MIR1285-2 regulates several cellular processes, including cell proliferation, apoptosis, and cell cycle, primarily through targeting mRNAs such as TGM2 (transglutaminase 2) and DAPK2 (Death-Associated Protein Kinase 2)[1][2]. In cancer contexts—including renal cell carcinoma and colorectal cancer—miR-1285-2 acts as a tumor suppressor or oncogenic factor depending on the cellular environment, with downregulation associated with increased cancer cell proliferation and invasion, and inhibition leading to anti-tumor effects via modulation of pro-apoptotic pathways[1][2][3].
Inhibition of microRNA function via anti-miR oligonucleotides can lead to derepression of tumor-suppressor genes (e.g., DAPK2)[2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 1285-2 (MIR1285-2).